Drug Utilization of Anti Hypertensives in CKD Patients: A Randomized Prospective Study at a Tertiary Care Teaching Hospital

  • Ashika M Ranjani Jawaharlal Nehru Technological University
  • Sahithi B Goud Jawaharlal Nehru Technological University
  • Amatul Wadood Sumayya Jawaharlal Nehru Technological University
  • Syeda Nabila Firdous Jawaharlal Nehru Technological University
  • Amatul Ali Sameera Jawaharlal Nehru Technological University
Keywords: Chronic Kidney Disease, Anti-Hypertensive drugs, Calcium channel blockers, Diuretics, β blockers, α blockers, Angiotensin receptor blockers, Angiotensin converting, enzymes, Vasodilators, Medication adherence

Abstract

AIMS AND OBJECTIVES: Our aim was to evaluate the clinical use of Antihypertensive drugs in patients with chronic Kidney disease at a tertiary care teaching hospital.

METHOD: An observational, prospective cohort study was conducted at a tertiary care teaching hospital in Hyderabad, T.S, India. A total of 184 patients from the inpatient department of nephrology Department at Gleneagles Global Hospitals, Bairamalguda, LB Nagar, Hyderabad. All information significant to the study was collected from the case records and discussions conducted with the in-patients and bystanders during ward rounds, with the support of a physician, which were analyzed by SPSS software. Moreover, daily follow-ups were conducted to assemble data on amendment in therapy, add-on therapy, and clinical improvement.

RESULTS: The Mean Age was 59.29 years and the standard deviation was 1.116 of the population, 60% were smokers and 40% were alcoholics. The most commonly used Class of anti-hypertensive drugs are Calcium channel blockers with percentage of 64.13%, Diuretics with percentage of 57.60%, β blockers with percentage of 43.47%. Whereas most commonly used Calcium channel blockers are Amlodipine with percentage of 52%, and Cilindipine with percentage of 9.10%.Diuretics are are Furosemide with percentage of 36.90% and Toresemide 11.40%. Most commonly used Adenergic Antagonist are in β Blockers are Metoprolol with percentage of 31.50%, In α blockers are prazosin with percentage of 26%, In α+β blocker are Carvedilol with percentage of 8.60%. Most commonly used ARB’s are Telmisartan with percentage of 6.50%, and ACE’s are Ramipril with percentage of 1%. Most commonly used central sympatholytics are Clonidine with percentage of 18.40%, Vasodilators are Minoxidil with percentage of 1%. Medication adherence have been done, In which patients with High Adherence are with percentage of 16.21%, Medium Adherence are with percentage of 45.94%, Low Adherence are with percentage of 37%. This is done by Morisky medication adherence scale 8.

CONCLUSION: We have concluded that the CCB’s, diuretics and β-blockers are the most commonly used anti-hypertensive classes in hypertensive patients with CKD. Use of anti-hypertensives in CKD patients does not deviate from the guidelines laid down by NKF KDOQI guidelines. The patients should be educated about the rational use of drugs to decrease medication adherence.

Author Biographies

Ashika M Ranjani, Jawaharlal Nehru Technological University

Dept. of Pharmacy Practice
Jawaharlal Nehru Technological University
Sheriguda, Ibrahimpatnam, Ranga Reddy, Telangana

Sahithi B Goud, Jawaharlal Nehru Technological University

Dept. of Pharmacy Practice
Jawaharlal Nehru Technological University
Sheriguda, Ibrahimpatnam, Ranga Reddy, Telangana

Amatul Wadood Sumayya, Jawaharlal Nehru Technological University

Dept. of Pharmacy Practice
Jawaharlal Nehru Technological University
Sheriguda, Ibrahimpatnam, Ranga Reddy, Telangana

Syeda Nabila Firdous, Jawaharlal Nehru Technological University

Dept. of Pharmacy Practice
Jawaharlal Nehru Technological University
Sheriguda, Ibrahimpatnam, Ranga Reddy, Telangana

Amatul Ali Sameera, Jawaharlal Nehru Technological University

Dept. of Pharmacy Practice
Jawaharlal Nehru Technological University
Sheriguda, Ibrahimpatnam, Ranga Reddy, Telangana

References

Abhisek PA., Panda R., Mohapatra J., et al., (2016); Antihypertensive drug utilisation pattern among chronic kidney disease patients undergoing maintenance dialysis in a tertiary care teaching hospital; J. Evolution Med. Dent. Sci; 5(50); 3207-3211.

Ajay Kumar Lal Das (2015); A Study on Prescribing Pattern of Antihypertensive drugs in Diabetic patients at a tertiary care teaching hospital; Int J Med Res Prof; 1(3); 118-121.

Al-Ramahi R (2012); Medication prescribing patterns among chronic kidney disease patients in a hospital in Malaysia; 23(2); 403-408.

Andrew S. Levey., Rocco MV, Anderson S, et al., (2004); K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease; American Journal of Kidney Diseases; 43(5); S1–S290.

Anju Madhwar., Dharmender Gupta., Sujata Singh., N. A. Ansari (2015); Drug Utilization Evaluation of Antihypertensive agents in nephrology department in tertiary care hospital; Indian Journal of Pharmacy and Pharmacology; 2(1); 10-15.

Arshad H. Mohd., Uday V. Mateti., Venkateswarlu Konuru., Mihir Y. Parmar. and Buchi R. Kunduru (2012); A study on prescribing patterns of anti hypertensives in geriatric patients; 3(4); 139-142.

Barbara G. Wells., Joseph T. Dipiro., Terry L. Schwinghammer. and Cecily V. DiPiro (2015), “Chronic Kidney Disease”, in Vimal K. Derebail, Abhijit V. Kshirsagar, and Melanie S. Joy, Handbook of Pharmacotherapy-A Pathophysiologic Approach, McGraw-Hill, New York, pp. 787 & pp. 798.

Bhanu Priya B. and Basavanna P L (2015); Pattern of antihypertensive drug utilisation among chronic kidney disease patients in a dialysis unit of a tertiary care hospital; International Journal of Biomedical Research; 6(4); 251-254.

British Kidney Patient Association (2006); Treatment of Hypertension in Chronic Kidney Disease.

Centers for Disease Control and Prevention (2018); Chronic Kidney Disease Surveillance System-United States. GA 30329-4027.

Chang A, Kramer H (2012); CKD progression: a risky business. Nephrol Dial Transplant; 27(7); 2607-2609.

Elahe Elhami (2015); Drug Utilization Evaluation Of Antihypertensive Drugs In Patients With Renal Failure; World Journal Of Pharmacy And Pharmaceutical Sciences; 5(1); 572-582.

Falodia J. and Singla MK (2012); CKD Epidemiology and Risk Factors; Clin Queries Nephrol; 20(1); 249–252.

Horowitz B., Miskulin D. and Zager P (2015); Epidemiology of Hypertension in CKD; Adv Chronic Kidney Dis.; 22(2); 88-95.

Iseki K (2005); Factors Influencing the Development of End Stage Renal Disease; Clin Exp Nephrol; 9(1); 5-14.

James L. and Holly MD (2013); Southeast Texas Medical Associates, LLP; Chronic-Renal-Disease Disease-Management.

Joseph T. Dipiro., Robert L. Talbert., Gary C. Yee., Gary R. Matzke., Barbara G. Wells. L. Michael Posey (2011); Chronic Kidney Disease; in Vimal K. Derebail, Abhijit V. Kshirsagar, and Melanie S. Joy, Text book of Pharmacotherapy-A pathophysiologic approach, McGraw-Hill, New York, pp. 775-796

Kasper., Braunwald., Fauci., Hauser., Longo. Jameson (2008), “Chronic Kidney Disease”, In; Dennis L. Kasper, Harrison Principles of Internal Medicine, McGraw Hill, New York, pp. 1682 & pp. 1685

Kidney Disease (2013); Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease; Kidney Int Suppl; 3; 1-150.

Kwakernaak AJ., Zelle DM., Bakker SJ. and Navis G (2013); Central body fat distribution associates with unfavorable renal hemodynamics independent of body mass index; J Am Soc Nephrol; 24(6); 987–994.

Lea JP. and Nicholas SB (2002); Diabetes mellitus and hypertension: key risk factors for kidney disease; J Natl Med Assoc; 94(8 Suppl); 7S-15S.

Mackenzie HS., Lawler EV. and Brenner BM (1999); Congenital Oligonephropathy: The Fatal Flaw in Essential Hypertension; Kidney Int Suppl; 55(1); S30-S34.

Mary Anne Koda-Kimble., Lloyd Yee Young., Brian K. Alldredge., Robin L. Corelli., B. Joseph Guglielmo., Wayne A. Kradjan. and Bradley R. Williams (2008), “Chronic Kidney Disease”, in Amy Barton Pai and Todd A. Conner, Textbook of Applied Therapeutics-The Clinical Use of Drugs, Lippincott Williams & Wilkins, Maryland, USA, pp. 31-1 to 31-10

McClellan WM. and Flanders WD (2003); Risk factors for progressive chronic kidney disease; J Am Soc Nephrol; 14(7 Suppl 2); S65-70.

Miller JA., Anacta LA. and Cattran DC (1999); Impact of Gender on Renal Response to Angiotensin II; Kidney Int; 55(1); 278-285.

Mirrakhimov AE (2012); Obstructive Sleep Apnea and Kidney Disease: is there any direct link?; Sleep Breath; 16(4); 1009-1016.

Myers GL., Miller WG., Coresh J., Fleming J., Greenberg N., Greene T. and National Kidney Disease Education Program Laboratory Working Group (2006); Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program; Clin Chem; 52; 5-18.

National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD (2012); The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) updated recommendations for treating patients with diabetes and CKD because of recent evidence changing previous recommendations; Am J Kidney Dis; 60(5); 850-886.

National Kidney Foundation-Hypertension: key risk factor for Chronic kidney disease. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKFKDOQI).

Neethu Joseph., Dr Yogananda R., Dr. Bharathi DR., Varsha Padman. Dr. Sandeep (2017); A Study on Prescription Pattern of Antihypertensive Agents in Chronic Renal Failure Patients and Assessment of Medication Adherence; Int. J. Pharm. Sci. Rev. Res; 45(2); 72-75.

Neugarten J. and Golestaneh L (2013); Gender and The Prevalence and Progression of Renal Disease; Adv Chronic Kidney D; 20(5); 390-395.

Noah Jarari., Narasinga Rao., Jagannadha Rao Peela., Khaled A. Ellafi., Srikumar Shakila., Abdul R. Said., Nagaraja Kumari Nelapalli., Yupa Min., Kin Darli Tun., Syed Ibrahim Jamallulail., Avinash Kousik Rawal., Ranjani Ramanujam., Ramesh Naidu Yedla., DhiliKumar Kandregula., Anuradha Argi. and Laxmi Teja Peela (2016); A review on prescribing patterns of antihypertensive drugs; Clin Hypertens; 22; 7

Peralta CA., Hicks LS., Chertow GM., Ayanian JZ., Vittinghoff E., Lin F. Shlipak MG (2005); Control of Hypertension in Adults With Chronic Kidney Disease in the United States; Hypertension; 45(6); 1119-1124.

Rajiv Ahlawat., Sanjay D’cruz. and Pramil Tiwari (2012); Drug Utilization Evaluation of Antihypertensive agents in nephrology department in tertiary care hospital; 3(1); 1000149

Ratcliffe PJ (1993); Molecular biology of erythropoietin; Kidney Int; 44(6); 887–904.

Ridao N., Luño J., García de Vinuesa S., Gómez F., Tejedor A. and Valderrábano F (2001); Prevalence of Hypertension in Renal Disease; Nephrol Dial Transplant; 16 Suppl 1; 70-73.

Roger Walker. and Cate Whittlesea (2012), “Chronic Kidney Disease and End-Stage Renal Disease”, in J. Marriott, P. Cockwell and S. Stringer, Textbook of Clinical Pharmacy and Therapeutics, Churchill Livingstone, Edinburgh, pp. 274-284

Shah J. Balraj A (2017); Drug utilization pattern of antihypertensive agents in patients of hypertensive nephropathy in a tertiary care hospital: a cross sectional study; Int J Basic Clin Pharmacol; 6(9); 2131-2133.

Silbiger S. and Neugarten J (2013); Gender and Human Chronic Renal Disease; Gend Med. 5; Suppl A; S3-S10.

Song EY., McClellan WM., Mc Clellan A., Gadi R., Hadley A.C., Krisher J., Clay M. and Freedman B.I (2013); Effect of community characteristics on familial clustering of end-stage renal disease; Am J Nephrolxpp; 30(6); 499-504.

Soumya Santra., Divya Agrawal., Sanjay Kumar., Sudhanshu Sekhar Mishra (2015); A Study on the Drug Utilization Pattern in Patients with Chronic Kidney Disease with Emphasis on Antibiotics; 2; 85-89.

Stevens LA., Coresh J., Greene T. and Levey AS (2015); Assessing kidney function-measured and estimated glomerular filtration rate; N Engl J Med; 354; 2473-83.

The UMHS Clinical Guideline on Chronic Kidney Disease (2013); Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

Toto RD (2005); Treatment of Hypertension in Chronic Kidney Disease; Semin Nephrol; 25(6); 435-439.

Vikse BE., Irgens LM., Leivestad T., Hallan S. and Iversen BM (2008); Low Birth Weight Increases Risk for End-Stage Renal Disease; J Am Soc Nephrol; 19(1); 151-157.

Published
2019-03-01
How to Cite
[1]
Ranjani, A.M., Goud, S., Sumayya, A., Firdous, S. and Sameera, A. 2019. Drug Utilization of Anti Hypertensives in CKD Patients: A Randomized Prospective Study at a Tertiary Care Teaching Hospital. PharmaTutor. 7, 3 (Mar. 2019), 41-72. DOI:https://doi.org/10.29161/PT.v7.i3.2019.41.
Section
Articles